Pain control after surgery often involves several different medications working together. Acetaminophen, anti-inflammatory drugs, local anesthetics, nerve blocks, and other non-opioid treatments can reduce pain, but opioids such as oxycodone, hydrocodone, morphine, fentanyl, or hydromorphone are still commonly used when postoperative pain is moderate or severe. As marijuana use has become more common, some surgical patients have begun adding medicinal cannabis to these medications in hopes of improving pain control, sleeping better, or reducing the amount of opioids they need.
The idea is biologically plausible because cannabinoids and opioids influence overlapping pain pathways, yet the clinical evidence is more complicated than the popular claim that marijuana automatically reduces opioid requirements. Large surgical studies have found that regular cannabis users often report more pain after surgery and sometimes require more opioids, while most randomized studies of cannabinoids for acute postoperative pain have failed to demonstrate a meaningful opioid-sparing effect. A few newer trials suggest certain pharmaceutical cannabinoids may eventually have a role in selected surgical settings, but cannabis cannot currently be considered a proven substitute for postoperative opioid medication.
Why Cannabis and Opioids Can Affect the Same Pain Pathways
Opioids reduce pain primarily by activating opioid receptors in the brain, spinal cord, and peripheral nervous system. Drugs such as oxycodone, hydrocodone, morphine, and fentanyl can produce powerful analgesia, but their effects also include sedation, nausea, constipation, impaired coordination, and respiratory depression. The latter is the most dangerous opioid effect because sufficiently high doses can suppress the brain’s drive to breathe.
THC works differently. It activates cannabinoid receptors, particularly CB1 receptors found throughout the central nervous system, and can change the way pain signals are transmitted and perceived. Laboratory research suggests that cannabinoid and opioid signaling systems interact at several points involved in pain processing, creating the theoretical possibility that activating both systems could provide greater analgesia than either drug alone. This possibility has fueled interest in cannabis as an “opioid-sparing” treatment.
Chronic pain research provides some support for that idea in selected circumstances. However, acute surgical pain is different from chronic neuropathic or musculoskeletal pain. Tissue injury, inflammation, nerve stimulation, movement, and wound healing all contribute to postoperative pain over a relatively short period. The American Society of Regional Anesthesia and Pain Medicine concluded in its 2023 consensus guideline that although low-dose THC may provide opioid-sparing effects in some chronic-pain patients, that benefit has not been demonstrated consistently in acute postoperative pain.
Cannabis Users Often Report More Pain After Surgery
One of the largest studies addressing this question came from Cleveland Clinic researchers and included 34,521 adults undergoing elective surgery. Of those patients, 1,683 reported cannabis use within 30 days before surgery. After researchers adjusted for differences between cannabis users and nonusers, cannabis use was associated with approximately 30 percent greater opioid consumption during the first 24 hours after surgery.
Cannabis users also reported more pain. Their average postoperative pain score was approximately 0.57 points higher on a standard pain scale than that of nonusers. Importantly, the study did not find a meaningful increase in postoperative hypoxemia or pulmonary complications among cannabis users. Because this was an observational study, it cannot prove that cannabis itself caused the increased pain or opioid use. People who use marijuana may differ from nonusers in pain sensitivity, tolerance, anxiety, prior substance exposure, or other factors. Nevertheless, the findings directly challenge the assumption that preoperative cannabis use reliably reduces postoperative opioid requirements.
The 2023 ASRA guideline reached a similar conclusion after reviewing the broader literature. The expert panel found evidence that cannabis users may experience higher postoperative pain scores and require more opioids. ASRA therefore recommends multimodal pain treatment and increased attention to adequacy of analgesia rather than automatically prescribing either more or fewer opioids simply because a patient uses cannabis.
Using Marijuana After Discharge Does Not Clearly Replace Opioids
Cannabis use after leaving the hospital has also been studied. Researchers using the Michigan Surgical Quality Collaborative examined 11,314 patients undergoing 16 common surgical procedures at 69 hospitals. Among them, 581 reported using cannabis specifically to treat their postoperative pain.
Instead of replacing opioid medication, cannabis users consumed approximately one additional opioid pill on average after adjustment for other factors. The difference was statistically significant but small enough that investigators considered it unlikely to be clinically important. The pain findings were more notable. Approximately 68 percent of patients using cannabis reported moderate-to-severe surgical-site pain one week after discharge compared with about 57 percent of patients who did not use cannabis. At one month, moderate-to-severe pain was reported by approximately 16.5 percent of cannabis users versus 9 percent of nonusers.
Cannabis users also reported lower satisfaction and quality-of-life scores after surgery. As with the Cleveland Clinic study, causation cannot be assumed. Patients with the worst postoperative pain may simply have been more likely to turn to marijuana for additional relief. Still, the Michigan study provides little support for routinely recommending cannabis as a way to replace prescribed postoperative opioids.
Randomized Trials Have Mostly Been Disappointing
A major systematic review led by researchers from the University of Toronto, University of Ottawa, Ohio State University, and Women’s College Hospital examined cannabinoids for acute postoperative pain. The analysis included eight randomized controlled trials involving 924 patients plus four observational studies totaling more than 4,000 additional patients. Researchers found no clinically important reduction in cumulative opioid consumption or pain at 24 hours when cannabinoids were added to conventional postoperative treatment.
Some results were actually unfavorable. Patients receiving cannabinoids had slightly higher pain scores at approximately 12 hours after surgery, and the odds of postoperative hypotension were more than three times higher than among control patients. The researchers concluded that cannabinoids had limited usefulness for acute postoperative pain and did not provide clinically important advantages over traditional analgesic treatment.
Individual trials have produced similarly mixed results. A randomized trial from the Université de Montréal tested the synthetic THC-like medication nabilone after major gynecological and orthopedic surgery. Nabilone did not reduce morphine consumption, and patients receiving the higher dose actually reported greater pain at rest and during movement. These findings are one reason cannabinoid treatments have not become routine components of postoperative pain protocols despite their effectiveness for certain chronic-pain conditions.
Newer Dronabinol Studies Show Why the Question Is Still Open
The evidence is not entirely negative. A small 2024 randomized study involving 68 patients undergoing coronary artery bypass graft surgery tested dronabinol, a pharmaceutical form of THC, as an adjunct to standard postoperative pain treatment. Patients receiving dronabinol required approximately 40 percent less opioid medication after surgery than the control group. Mechanical ventilation time and intensive-care length of stay did not differ significantly.
Those findings generated considerable interest, but the trial was small and involved a highly specific cardiac-surgery population. It therefore cannot establish that cannabis flower, edibles, or THC products will reduce opioid use after routine orthopedic, abdominal, dental, or outpatient surgery.
A larger 2026 randomized double-blind study from Hospital for Special Surgery, Weill Cornell Medicine, and collaborating institutions tested perioperative dronabinol in patients undergoing total knee replacement. The investigators found essentially identical opioid consumption during the first 24 hours—about 15 morphine-milligram equivalents in both the dronabinol and placebo groups. Opioid requirements between 24 and 48 hours were numerically lower with dronabinol but did not reach statistical significance, and pain scores were not significantly different. The contrast between these trials illustrates why researchers still cannot recommend cannabinoids as a reliable postoperative opioid-sparing strategy.
Cannabis and Opioid Respiratory Depression
Combining psychoactive drugs naturally raises concern about respiratory depression. Opioids can substantially suppress ventilation, particularly when doses are high or when they are combined with alcohol, benzodiazepines, sleep medications, or other respiratory depressants. THC can cause sedation and cognitive impairment but does not normally produce opioid-like respiratory suppression by itself.
A randomized controlled crossover trial published in the British Journal of Anaesthesia directly examined this issue in 18 healthy volunteers. Participants received either placebo or 20 milligrams of oral oxycodone followed by inhaled high-THC cannabis. Oxycodone reduced ventilatory response to elevated carbon dioxide by approximately 30 percent. Adding inhaled THC did not further suppress breathing, although sedation increased slightly.
That result is reassuring but should not be interpreted as proof that combining cannabis with opioids after surgery is risk-free. The participants were young, healthy volunteers under close medical supervision rather than patients recovering from anesthesia, experiencing surgical stress, receiving multiple sedating medications, or living with sleep apnea, obesity, lung disease, kidney impairment, or advanced age. ASRA therefore states that opioids can be used when medically indicated in cannabis users but recommends increased vigilance.
Sedation and Impairment May Be the More Immediate Problem
Even if THC does not substantially amplify opioid respiratory depression under every circumstance, combining it with opioid medication can increase functional impairment. Both can cause sleepiness, dizziness, slowed reaction time, confusion, impaired judgment, nausea, and difficulty maintaining balance. After surgery, these problems occur during a period when the patient may already be weak, dehydrated, sleep deprived, or recovering from anesthesia.
Falls are particularly concerning after orthopedic surgery, spine surgery, or procedures in older adults. A person may feel that marijuana is making them comfortable while simultaneously becoming too impaired to walk safely, manage stairs, or remember when the last opioid dose was taken. This creates the possibility of accidental medication errors in addition to injury.
Alcohol, benzodiazepines such as alprazolam or diazepam, prescription sleep medications, sedating antihistamines, gabapentin, pregabalin, and some muscle relaxers can add still more CNS depression. The risk profile of oxycodone plus a small THC dose is therefore very different from oxycodone plus a strong edible, alcohol, and a bedtime sedative.
Regular Cannabis Use May Change Postoperative Pain Sensitivity
One possible explanation for greater postoperative pain among regular cannabis users is tolerance. Repeated THC exposure causes adaptations within the endocannabinoid system, including changes in CB1 receptor availability. As tolerance develops, larger cannabis doses may be required to produce the same effect.
Researchers have also raised the possibility of cannabinoid-associated hyperalgesia in some long-term users—a situation in which repeated exposure may increase rather than decrease sensitivity to acute pain. The mechanism remains uncertain and may involve changes in cannabinoid receptors, TRPV1 signaling, or other pain-processing pathways. ASRA notes that dose-dependent hyperalgesia is one possible contributor to the higher pain scores and opioid requirements seen in some cannabis-using surgical patients.
A 2025 review examining 42 studies of preoperative cannabis exposure found considerable inconsistency but an overall pattern worth noting. Fourteen studies reported greater postoperative pain among cannabis users, while only two suggested less pain. Eighteen studies found greater opioid requirements, while only three reported reduced opioid use. The authors emphasized substantial differences among surgical populations and cannabis-use definitions, but the findings again argue against assuming marijuana will automatically improve postoperative analgesia.
Long-Term Opioid Use May Be a Different Question
Short-term postoperative opioid consumption and long-term opioid dependence are not necessarily the same issue. Some observational studies have suggested that people who use cannabis may be less likely to remain on high-dose opioids months after certain operations. For example, a 2024 study of lumbar-fusion patients found that cannabis users were less likely to be using opioids at two and six months and were less likely to receive very high opioid doses during part of the early recovery period.
These results are interesting but should be interpreted cautiously. Database studies cannot determine why cannabis users stopped opioids sooner, whether they substituted cannabis directly, whether their physicians prescribed differently, or whether other patient characteristics explained the difference. They also do not contradict findings showing that cannabis users may need equal or greater analgesia during the immediate postoperative period. Cannabis could theoretically have one relationship with acute surgical pain and another with longer-term chronic pain.
THC and CBD Should Not Be Treated as the Same Treatment
THC is the cannabinoid most strongly associated with analgesia, intoxication, altered perception, and sedation. CBD generally produces much less intoxication and is often marketed as a safer pain treatment, yet evidence supporting CBD alone for acute postoperative pain is weak. A 2026 University of Minnesota review of cannabis and CBD following orthopedic surgery found mixed results for CBD-only treatments and only modest evidence that THC/CBD combinations might reduce opioid requirements.
CBD also has significant drug-interaction potential at higher doses because it can inhibit liver enzymes involved in processing prescription medications. Some opioids, including oxycodone, hydrocodone, and tramadol, depend partly on cytochrome P450 metabolism. Researchers have not established a standardized postoperative CBD dose that can safely be used with these medications, making concentrated CBD oils and large oral doses particularly difficult to evaluate.
For this reason, saying that someone uses “cannabis” is not enough information for a surgical team. A 5-milligram THC edible, a high-potency vape, a CBD isolate containing hundreds of milligrams, and smoked marijuana produce very different pharmacological exposures.
A Multimodal Pain Plan Remains the Better-Supported Approach
Current anesthesiology guidance favors multimodal analgesia after surgery. This means combining treatments that act through different mechanisms so that no single drug needs to carry the entire burden of pain control. Depending on the procedure and patient’s medical history, this may include acetaminophen, NSAIDs, regional nerve blocks, local anesthetics, ice, physical positioning, rehabilitation, and selected neuropathic-pain medications, with opioids reserved for pain that remains inadequately controlled.
ASRA specifically recommends multimodal analgesia and regional anesthesia when appropriate for cannabis users, with opioids available as rescue medication rather than automatically increasing or decreasing the prescribed dose. There is currently insufficient evidence to recommend routinely changing a postoperative opioid prescription solely because someone uses cannabinoids.
Patients who regularly use marijuana should tell the surgeon and anesthesia team before the procedure and should also ask when it is appropriate to resume cannabis during recovery. Someone using cannabis medically every day may need a different plan from an occasional recreational user. Starting or dramatically increasing cannabis immediately after surgery without discussing it with the clinical team makes medication effects more difficult to predict.
Warning Signs When Cannabis and Opioids Are Used Together
Ordinary sleepiness can occur with either cannabis or opioid medication, but extreme sedation should not be dismissed. A person who is unusually difficult to awaken, has slow or shallow breathing, repeatedly falls asleep while attempting to speak, develops blue or gray lips, becomes severely confused, or loses consciousness requires emergency medical attention. Naloxone should be used when available if opioid overdose is suspected, followed by emergency medical care.
Less dramatic symptoms—including repeated dizziness, faintness, severe nausea, unusual confusion, or inability to walk safely—also deserve attention because postoperative patients can deteriorate quickly when dehydration, blood loss, medication interactions, or infection are present. Cannabis should never be used to conceal steadily worsening surgical pain without determining why the pain is increasing.
Severe pain that suddenly worsens, especially when accompanied by fever, expanding swelling, difficulty breathing, chest pain, new weakness, or abnormal wound drainage, may represent a surgical complication rather than inadequate pain medication.
Final Thoughts on Cannabis and Opioid Pain Medication After Surgery
Cannabis has a legitimate role in modern pain research, but current evidence does not support routinely recommending marijuana as a replacement for opioid medication after surgery. Large Cleveland Clinic and Michigan studies found that cannabis users tended to report more postoperative pain and did not use fewer opioids. A major University of Toronto-led meta-analysis likewise found no meaningful opioid-sparing advantage from perioperative cannabinoids and identified increased postoperative hypotension. ASRA consequently concludes that the opioid-sparing effects sometimes observed in chronic pain have not been convincingly demonstrated for acute surgical pain.
There are important exceptions worth studying. A small cardiac-surgery trial found substantially lower opioid use with dronabinol, while other observational studies suggest cannabis might be associated with lower long-term opioid use after selected procedures. Yet the newer Hospital for Special Surgery randomized knee-replacement trial found no significant reduction in early opioid use or pain with dronabinol. The overall evidence therefore remains mixed rather than showing a reliable postoperative benefit.
For someone already using marijuana, the most important issue is not necessarily stopping cannabis forever but making sure the surgical and anesthesia teams know about it. THC dose, CBD dose, frequency of use, route of administration, opioid type, other sedating medications, sleep apnea, lung disease, and the type of surgery all change the risk-benefit calculation. Opioids should be taken only as directed, cannabis should not be used as a reason to independently increase or decrease opioid doses, and combining either substance with alcohol or additional sedatives can make postoperative recovery considerably more hazardous. Until stronger clinical trials establish who benefits, cannabis is best considered an individualized and still-experimental adjunct to postoperative pain management rather than a proven opioid substitute.
